Comparative Risk of Alzheimer Disease and Related Dementia Among Medicare Beneficiaries With Rheumatoid Arthritis Treated With Targeted Disease-Modifying Antirheumatic Agents
Sign Up to like & getrecommendations! Published in 2022 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2022.6567
Abstract: Key Points Question Is use of targeted disease-modifying antirheumatic drugs associated with risk of Alzheimer disease and related dementia (ADRD)? Findings In this cohort study including 22 569 propensity score–matched patient pairs, initiation of inhibitors of… read more here.
Keywords: risk alzheimer; disease; targeted disease; disease modifying ... See more keywords
The Impact of In‐Hospital Disease Modifying Treatments on Mental and Physical Burden in Caregiver of Patients With MS
Sign Up to like & getrecommendations! Published in 2025 at "Annals of Clinical and Translational Neurology"
DOI: 10.1002/acn3.70026
Abstract: People with multiple sclerosis (pwMS) may require a high level of daily assistance both for indoor and outdoor activities. Usually, relatives or friends provide daily support to MS patients who have lost personal autonomy. Several… read more here.
Keywords: disease; impact hospital; hospital disease; disease modifying ... See more keywords
Real‐World Effectiveness of Initial Disease‐Modifying Therapies in Pediatric Multiple Sclerosis
Sign Up to like & getrecommendations! Published in 2020 at "Annals of Neurology"
DOI: 10.1002/ana.25737
Abstract: To assess real‐world effectiveness of initial treatment with newer compared to injectable disease‐modifying therapies (DMTs) on disease activity in pediatric multiple sclerosis (MS) and clinically isolated syndrome (CIS). read more here.
Keywords: real world; effectiveness initial; world effectiveness; modifying therapies ... See more keywords
Evaluation of liver parenchyma with shear wave elastography in patients with rheumatoid arthritis receiving disease‐modifying antirheumatic drug therapy
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Ultrasound"
DOI: 10.1002/jcu.23847
Abstract: Methotrexate (MTX) and leflunomide (LEF) play fundamental roles in rheumatoid arthritis (RA) treatment and require proper monitoring of side effects. Concerns about MTX/LEF‐related liver fibrosis (LF) in patients with RA remain unclear. This study investigated… read more here.
Keywords: shear wave; wave elastography; rheumatoid arthritis; antirheumatic drug ... See more keywords
Biomarker‐driven phenotyping in Parkinson's disease: A translational missing link in disease‐modifying clinical trials
Sign Up to like & getrecommendations! Published in 2017 at "Movement Disorders"
DOI: 10.1002/mds.26913
Abstract: Past clinical trials of putative neuroprotective therapies have targeted PD as a single pathogenic disease entity. From an Oslerian clinicopathological perspective, the wide complexity of PD converges into Lewy bodies and justifies a reductionist approach… read more here.
Keywords: medicine; parkinson; disease modifying; disease ... See more keywords
Use and safety of disease‐modifying therapy in pregnant women with multiple sclerosis
Sign Up to like & getrecommendations! Published in 2019 at "Pharmacoepidemiology and Drug Safety"
DOI: 10.1002/pds.4735
Abstract: The purpose of this study is to describe dispensing patterns and comparative safety of disease‐modifying therapies (DMTs) during pregnancy in women with multiple sclerosis (MS). read more here.
Keywords: women multiple; safety; disease modifying; safety disease ... See more keywords
Trends in the use of disease‐modifying therapies among reproductive‐aged women with multiple sclerosis in the United States from 2010 to 2019
Sign Up to like & getrecommendations! Published in 2022 at "Pharmacoepidemiology and Drug Safety"
DOI: 10.1002/pds.5411
Abstract: Multiple sclerosis (MS) is a chronic disease of the central nervous system that disproportionately affects women, with typical onset during reproductive age. Several disease‐modifying therapies (DMTs) are FDA‐approved to slow disease progression, but are not… read more here.
Keywords: modifying therapies; 2010 2019; disease modifying; multiple sclerosis ... See more keywords
Longitudinal changes of swallowing safety and efficiency in infants with spinal muscular atrophy who received disease modifying therapies
Sign Up to like & getrecommendations! Published in 2024 at "Pediatric Pulmonology"
DOI: 10.1002/ppul.26919
Abstract: Dysphagia is a common feature of the natural history of patients with spinal muscular atrophy (SMA). Literature regarding swallowing safety and efficiency is scarce in patients with SMA, particularly in the era of newborn screening… read more here.
Keywords: spinal muscular; swallowing safety; muscular atrophy; disease modifying ... See more keywords
Biological disease‐modifying drugs for rheumatoid arthritis
Sign Up to like & getrecommendations! Published in 2020 at "Prescriber"
DOI: 10.1002/psb.1836
Abstract: There are now nine biological disease‐modifying antirheumatic drugs (bDMARDs) available for the treatment of rheumatoid arthritis – seven monoclonal antibodies and two fusion proteins. This article summarises their indications, efficacy, place in therapy and adverse… read more here.
Keywords: drugs rheumatoid; disease modifying; biological disease; rheumatoid arthritis ... See more keywords
[Disease-modifying treatment approaches for Alzheimer's disease].
Sign Up to like & getrecommendations! Published in 2021 at "Der Nervenarzt"
DOI: 10.1007/s00115-021-01222-w
Abstract: Alzheimer's disease is one the major common diseases but so far only with symptomatic treatment options. New insights define the disease as a slowly progressive continuum with very long preclinical and early symptomatic phases. Innovative molecular… read more here.
Keywords: alzheimer disease; treatment; disease modifying; disease ... See more keywords
Scoping review of biosimilar disease-modifying antirheumatic drugs in pregnancy: evidence gaps and proposed outcome reporting framework
Sign Up to like & getrecommendations! Published in 2025 at "Rheumatology International"
DOI: 10.1007/s00296-025-05968-3
Abstract: Biologic disease-modifying antirheumatic drugs (DMARDs) have revolutionized the management of autoimmune diseases. Biosimilar DMARDs have emerged as highly similar, cost-efficient alternatives; however, the scope of their perinatal evidence remains unexplored. We conducted a scoping review… read more here.
Keywords: disease; evidence; pregnancy; disease modifying ... See more keywords